Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 11/20 | 0.35 |
| ▸ | PAICS | P22234 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | KIF5B | P33176 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ETV6 | P41212 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545160 | 1.00 | CNR2 (0.36) | CNR2CNR1KDM4EMAPTMAPK1 | |
| SCHEMBL543341 | 0.87 | CNR2 (0.37) | CNR2CNR1CTSAPAICSKDR | |
| SCHEMBL543342 | 0.87 | CNR2 (0.37) | CNR2CNR1CTSAPAICSKDR | |
| SCHEMBL543343 | 0.87 | CNR2 (0.37) | CNR2CNR1CTSAPAICSKDR | |
| SCHEMBL544335 | 0.84 | KMO (0.41) | KDM4EMAPTMAPK1ATMPAICS | |
| SCHEMBL545223 | 0.83 | ITGB1 (0.43) | CTSA | |
| SCHEMBL545222 | 0.83 | ITGB1 (0.43) | CTSA | |
| SCHEMBL544274 | 0.82 | ITGB1 (0.49) | CTSA | |
| SCHEMBL544754 | 0.82 | CTSA (0.41) | CTSA | |
| Bicarbonate SCHEMBL16493592 | 0.80 | CNR1 (0.44) | CNR2CNR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059508-B1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI SA (FR) | 2012-04-11 | — | — | EP | claimed |
| US-8110579-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists | SANOFI-AVENTIS (FR) | 2012-02-07 | — | — | US | claimed |
| US-20090318473-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI AVENTIS | 2009-12-24 | — | — | US | claimed |
| US-8552201-B2 | 5, 6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS | 2012-05-03 | — | — | US | disclosed |
| EP-2059508-B1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI SA (FR) | 2012-04-11 | — | — | EP | disclosed |
| US-8110579-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists | SANOFI-AVENTIS (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20090318473-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI AVENTIS | 2009-12-24 | — | — | US | disclosed |
| EP-2059508-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008020124-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318473-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | CNR2 15/4885CNR1 51/4885KDM4E 3338/4885 |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | CNR2 15/4885CNR1 51/4885KDM4E 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.